What is Kailera Therapeutics?
Headquartered in Waltham, Massachusetts, and San Diego, California, Kailera Therapeutics is a clinical-stage biotechnology company dedicated to transforming the treatment landscape for obesity. The firm focuses on developing a broad, differentiated portfolio of therapies that utilize multiple mechanisms of action and diverse routes of delivery. By prioritizing patient-centric innovation, Kailera aims to provide scalable, effective interventions that elevate overall health outcomes. The company's market position is defined by its commitment to rigorous scientific execution and its ability to attract high-caliber institutional backing, which has been instrumental in its rapid transition from early-stage development to a publicly traded entity.
How much funding has Kailera Therapeutics raised?
Kailera Therapeutics has raised a total of $1.6B across 3 funding rounds:
Series A
$400M
Series B
$600M
IPO
$625M
Series A (2024): $400M with participation from RTW Investments, Atlas Venture, Bain Capital, and Lyra Capital
Series B (2025): $600M led by Qatar Investment Authority, Bain Capital Private Equity, Perseverance Capital, Royalty Pharma, and Invus
IPO (2026): $625M, investors not publicly disclosed
Key Investors in Kailera Therapeutics
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, from company creation to public companies.
Atlas Venture
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
Bain Capital
Bain Capital is one of the worlds leading private investment firms, applying deep sector expertise and broad capabilities to drive innovation and unlock long-term value.
What's next for Kailera Therapeutics?
With the recent capital infusion, Kailera Therapeutics is poised to accelerate its clinical-stage pipeline, focusing on the successful execution of late-stage trials and the potential commercialization of its lead candidates. The strategic deployment of these funds will likely prioritize the expansion of manufacturing capabilities and the strengthening of its research infrastructure to support a diversified portfolio. As the company navigates the post-IPO landscape, the focus will shift toward achieving regulatory milestones and establishing a competitive footprint in the rapidly evolving weight management market. Investors will be closely monitoring the firm's ability to translate its scientific platform into tangible therapeutic value, ensuring long-term sustainability and market leadership in the biopharma space.
See full Kailera Therapeutics company page
